Loading...
Avalon Globocare Corp (ALBT) has experienced a significant price surge recently, driven by positive news catalysts such as its acceptance into the AMD AI Developer Program. However, the company's financial performance remains weak, with declining net income and EPS. Technical indicators show mixed signals, with a bullish MACD but bearish moving averages. Given the investor's long-term strategy and beginner level, it is advisable to hold off on purchasing this stock until there is more evidence of sustainable growth or improved financial performance.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is in the neutral zone, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), suggesting caution. The stock has surged significantly, but it is trading near resistance levels (R1: 1.125, R2: 1.326), which could limit further upside in the short term.
Acceptance into the AMD AI Developer Program, which enhances the company's AI capabilities.
Recent private placement financing to repay debts and support working capital.
Weak financial performance in the latest quarter, with a significant drop in net income (-84.86% YoY) and EPS (-96.70% YoY).
Bearish moving averages, indicating potential resistance to further price increases.
In Q3 2025, revenue increased slightly by 1.43% YoY to $350,099. However, net income dropped significantly by -84.86% YoY to -$254,268, and EPS fell by -96.70% YoY to -$0.06. Gross margin improved to 33.06%, up 14.51% YoY, but overall financial performance remains weak.
No data available for analyst ratings or price target changes.
